Sage Journals: Discover world-class research

Abstract

Objectives

Urinary biomarkers may help in identification, treatment and assessment of response in patients with lupus nephritis (LN). Osteoprotegerin (OPG) is produced by the kidneys and lymphoid cells and may reflect renal disease activity better. The data on its utility are sparse.

Methods

Fifty-eight patients with active LN (AN), 24 with active non-renal disease (ANR) and 39 with inactive disease (ID) were included. Median disease duration was 32 (1–204) months and median age was 27 (12–50) years. AN patients were followed up every three months for one year. Urine and serum samples were collected for OPG measurement by ELISA (pg/ml) and urinary values were normalised for creatinine excretion (pg/mg). Urine samples from 24 healthy individuals (HCs) and 20 patients each of rheumatoid arthritis (RA) and diabetic nephropathy (DM) served as controls. Variables were expressed as median (range).

Results

At baseline, normalised urinary OPG (uOPG) was significantly higher (p < 0.001) in AN (1229 (0–8577)) than ANR (236 (0–14713)), ID (463 (7–4253)), HCs (366 (120–2849)) and DM (350 (127–1577)) but it was not different from RA (1511 (122–8849)). uOPG correlated modestly with rSLEDAI (r = 0.4, p < 0.001) and SLEDAI (r = 0.31, p < 0.001) but not with serum OPG (sOPG). uOPG but not sOPG could differentiate between AN and ANR groups. In the longitudinal study, uOPG and sOPG decreased significantly with treatment at all follow-up visits but the trend of fall in sOPG was erratic. uOPG values at baseline, 3, 6, 9 and 12 months were 1229 (0–8577), 466 (3–4874), 104 (0–1598), 325 (0–4025) and 555 (6–6771) pg/mg, respectively. uOPG but not sOPG rose before conventional markers in three patients who had a relapse of LN. In two patients who developed chronic kidney disease, uOPG remained persistently high. For differentiating AN from ANR patients, uOPG performed the best on receiver operator characteristics analysis (AUC = 0.72) when compared with anti-dsDNA antibodies, C3, C4 and sOPG.

Conclusion

uOPG is derived from kidneys and helps differentiate active SLE patients with and without LN. It shows modest correlation with disease activity and has a potential to predict poor response to therapy and relapse of LN.

Keywords

SLE lupus nephritis biomarker urinary osteoprotegerin

Get full access to this article

View all access options for this article.

References

Wilhelmus

Cook

Noël

. Interobserver agreement on histopathological lesions in class III or IV lupus nephritis. Clin J Am Soc Nephrol 2015; 1: 47–53.

Misra

Gupta

. Biomarkers in lupus nephritis. Int J Rheum Dis 2015; 18: 219–232.

Yun

Chaudhary

Shu

. OPG/FDCR-1, a TNF receptor family member, is expressed in lymphoid cells and is up-regulated by ligating CD40. J Immunol 1998; 161: 6113–6121.

Simonet

Lacey

Dunstan

. Osteoprotegerin: A novel secreted protein in the regulation of bone density. Cell 1997; 89: 309–319.

Hochberg

. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725–1725.

Hahn

McMahon

Wilkinson

. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken) 2012; 64: 797–808.

Renal Disease Subcommittee of the American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Response Criteria. The American College of Rheumatology response criteria for proliferative and membranous renal disease in systemic lupus erythematosus clinical trials. Arthritis Rheum 2006; 54: 421–432.

Nasri

Ahmadi

Baradaran

. Clinicopathological correlations in lupus nephritis; a single center experience. J Nephropathol 2014; 3: 115–120.

Klimek

Skalska

Kwaśny-Krochin

. Differential associations of inflammatory and endothelial biomarkers with disease activity in rheumatoid arthritis of short duration. Mediators Inflamm 2014; 2014: 681635–681635.

10.

Świerkot

Gruszecka

Matuszewska

Wiland

. Assessment of the effect of methotrexate therapy on bone metabolism in patients with rheumatoid arthritis. Arch Immunol Ther Exp (Warsz) 2015; 63: 397–404.

11.

Kiani

Johnson

Chen

. Urine osteoprotegerin and monocyte chemoattractant protein-1 in lupus nephritis. J Rheumatol 2009; 36: 2224–2230.

12.

El-Shehaby

Darweesh

El-Khatib

. Correlations of urinary biomarkers, TNF-like weak inducer of apoptosis (TWEAK), osteoprotegerin (OPG), monocyte chemoattractant protein-1 (MCP-1), and IL-8 with lupus nephritis. J Clin Immunol 2011; 31: 848–856.

13.

Zannettino

Holding

Diamond

. Osteoprotegerin (OPG) is localized to the Weibel-Palade bodies of human vascular endothelial cells and is physically associated with von Willebrand factor. J Cell Physiol 2005; 204: 714–723.

14.

Collin-Osdoby

Rothe

Anderson

. Receptor activator of NF-kB and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis. J Biol Chem 2001; 276: 20659–20672.

15.

Benito-Martin

Ucero

Zubiri

. Osteoprotegerin in exosome-like vesicles from human cultured tubular cells and urine. PLoS One 2013; 8: e72387–e72387.

16.

Gupta

Yadav

Misra

Aggarwal

. Urinary sCD25 as a biomarker of lupus nephritis disease activity. Lupus 2015; 24: 273–279.

17.

Zauli

Corallini

Bossi

. Osteoprotegerin increases leukocyte adhesion to endothelial cells both in vitro and in vivo. Blood 2007; 110: 536–543.

18.

Silva

Branco

. Rank/Rankl/opg: Literature review. Acta Reumatol Port 2011; 36: 209–218.

19.

Wright

McCarthy

Middleton

Marshall

. RANK, RANKL and osteoprotegerin in bone biology and disease. Curr Rev Musculoskelet Med 2009; 2: 56–64.

20.

Hofbauer

Khosla

Dunstan

. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res 2000; 15: 2–12.

21.

Montañez-Barragán

Gómez-Barrera

Sanchez-Niño

Ucero

González-Espinoza

Ortiz

. Osteoprotegerin and kidney disease. J Nephrol 2014; 27: 607–617.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.15 MB